Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Recommendation of “Moderate Buy” by Analysts

Posted by on Aug 20th, 2026

Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $140.5333.

Several equities analysts have commented on PTGX shares. Truist Financial raised their price objective on Protagonist Therapeutics from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, August 10th. The Goldman Sachs Group raised shares of Protagonist Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $110.00 to $186.00 in a research report on Monday, August 10th. Wolfe Research initiated coverage on shares of Protagonist Therapeutics in a research report on Thursday, May 21st. They set an “outperform” rating and a $135.00 price target for the company. BMO Capital Markets boosted their price objective on shares of Protagonist Therapeutics from $112.00 to $178.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Weiss Ratings raised shares of Protagonist Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th.

Check Out Our Latest Report on PTGX

Insider Buying and Selling

In related news, Director William D. Waddill sold 9,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total value of $1,061,460.00. Following the sale, the director owned 7,825 shares in the company, valued at $922,880.50. This represents a 53.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 34,239 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $148.52, for a total value of $5,085,176.28. Following the transaction, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at approximately $77,746,952.56. This trade represents a 6.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 127,000 shares of company stock worth $17,818,139. Insiders own 5.19% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Farther Finance Advisors LLC grew its holdings in shares of Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after buying an additional 156 shares during the last quarter. Greenline Wealth Management LLC bought a new stake in shares of Protagonist Therapeutics during the fourth quarter valued at approximately $27,000. Keating Financial Advisory Services Inc. purchased a new position in Protagonist Therapeutics in the 2nd quarter worth approximately $30,000. Allworth Financial LP purchased a new position in Protagonist Therapeutics in the 2nd quarter worth approximately $31,000. Finally, Quantbot Technologies LP bought a new position in Protagonist Therapeutics in the 2nd quarter valued at approximately $42,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Stock Performance

PTGX stock opened at $154.94 on Thursday. Protagonist Therapeutics has a fifty-two week low of $54.50 and a fifty-two week high of $160.81. The company has a market capitalization of $10.03 billion, a price-to-earnings ratio of 150.43 and a beta of 1.78. The business’s 50 day moving average price is $132.99 and its two-hundred day moving average price is $109.36.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.02. The company had revenue of $213.47 million for the quarter, compared to analyst estimates of $212.03 million. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%.The firm’s quarterly revenue was up 3746.8% compared to the same quarter last year. Sell-side analysts forecast that Protagonist Therapeutics will post 4.22 earnings per share for the current year.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.

Featured Articles

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.